Pharma players in green on AbbVie/Allergan deal

Members of Big Biopharma, with the notable exception of AbbVie, are all enjoying a spike in buying after its $63B bid for Allergan, stoking hopes that big healthcare mergers are back in play.

Selected tickers: Takeda (TAK +1.3%), Bausch Health Companies (BHC+4.2%), Roche (OTCQX:RHHBY +0.2%), AstraZeneca (AZN +0.2%), Bristol-Myers Squibb (BMY +1%), GlaxoSmithKline (GSK +0.6%), Johnson & Johnson (JNJ +0.6%), Eli Lilly (LLY +0.7%), Merck (MRK), Novartis (NVS+0.7%), Pfizer (PFE +0.6%), Teva Pharmaceutical Industries (TEVA+6.4%), Amgen (AMGN +0.9%), Biogen (BIIB +3.1%), Gilead Sciences (GILD +1%), Vertex Pharmaceuticals (VRTX +0.3%)

ETFs: (XPH +3.4%), (XBI +0.9%), (IBB +0.9%), (PJP +1.2%), (IHE+2.3%), (PPH +0.6%), (XLV +0.1%)

https://seekingalpha.com/news/3473634-pharma-players-green-abbvie-allergan-deal